Short Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Rises By 123.8%

Key Points

• Short interest in SOPHiA GENETICS increased by 123.8% in July, rising from 16,000 shares to 35,800 shares, with 0.1% of the company's shares currently sold short.
• Institutional investors now own 31.59% of SOPHiA GENETICS, with multiple firms like Dimensional Fund Advisors and Federated Hermes significantly increasing their stakes.
• The company's stock opened at $3.30 with a market cap of $220.08 million and a negative earnings per share trend, missing consensus estimates in its last quarterly report.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) was the target of a significant increase in short interest in the month of July. As of July 15th, there was short interest totaling 35,800 shares, anincreaseof123.8% from the June 30th total of 16,000 shares. Approximately0.1% of the company's stock are sold short. Based on an average trading volume of 75,000 shares, the short-interest ratio is currently 0.5 days. Based on an average trading volume of 75,000 shares, the short-interest ratio is currently 0.5 days. Approximately0.1% of the company's stock are sold short.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of SOPH. Dimensional Fund Advisors LP raised its position in SOPHiA GENETICS by 23.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 21,619 shares of the company's stock valued at $68,000 after purchasing an additional 4,115 shares in the last quarter. Silverberg Bernstein Capital Management LLC boosted its stake in SOPHiA GENETICS by 54.4% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 34,675 shares of the company's stock worth $115,000 after acquiring an additional 12,211 shares in the last quarter. Ridgewood Investments LLC increased its holdings in shares of SOPHiA GENETICS by 1,930.5% during the first quarter. Ridgewood Investments LLC now owns 40,610 shares of the company's stock valued at $135,000 after acquiring an additional 38,610 shares in the last quarter. Federated Hermes Inc. lifted its position in SOPHiA GENETICS by 40.5% in the 4th quarter. Federated Hermes Inc. now owns 100,000 shares of the company's stock valued at $312,000 after acquiring an additional 28,819 shares in the last quarter. Finally, Bank Pictet & Cie Europe AG boosted its holdings in SOPHiA GENETICS by 14.4% during the 1st quarter. Bank Pictet & Cie Europe AG now owns 255,200 shares of the company's stock worth $847,000 after acquiring an additional 32,200 shares during the last quarter. Institutional investors and hedge funds own 31.59% of the company's stock.

SOPHiA GENETICS Stock Up 3.6%

NASDAQ SOPH traded up $0.12 on Tuesday, reaching $3.42. The company had a trading volume of 1,040,772 shares, compared to its average volume of 32,921. The company's fifty day moving average is $3.20 and its 200-day moving average is $3.27. The firm has a market capitalization of $228.08 million, a price-to-earnings ratio of -3.42 and a beta of 1.00. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.94 and a current ratio of 3.11. SOPHiA GENETICS has a 1-year low of $2.58 and a 1-year high of $4.92.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.05). The company had revenue of $17.78 million during the quarter, compared to the consensus estimate of $16.76 million. SOPHiA GENETICS had a negative net margin of 98.51% and a negative return on equity of 63.47%. On average, research analysts forecast that SOPHiA GENETICS will post -0.96 earnings per share for the current fiscal year.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.